Serina TherapeuticsFRA:2BO +8.03%19 ROA % is -161.54% as of Mar. 2026. GuruFocus rates FRA:2BO with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 1,419 Biotechnology companies, Serina Therapeutics ranks worse than 92.18% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Serina Therapeutics's annualizedNet Income for the quarter that ended in Mar. 2026 was €-23.87 Mil.
Serina Therapeutics's average Total Assets over the quarter that ended in Mar. 2026 was €14.78 Mil. Therefore, Serina Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -161.54%.
The historical rank and industry rank for Serina Therapeutics's ROA % or its related term are showing as below:
FRA:2BO'
s ROA % Range Over the Past 10 Years
Min: -280.54 Med: -142 Max: 107.25
Current: -170.59
During the past 5 years, Serina Therapeutics's highest ROA % was 107.25%. The lowest was -280.54%. And the median was -142.00%.
FRA:2BO's ROA % is ranked worse than 92.18% of 1419
companies
in the Biotechnology industry
Industry Median: -32.84
vs FRA:2BO: -170.59
Serina Therapeutics (FRA:2BO) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Serina Therapeutics ROA % Related Terms
Serina Therapeutics ROA % Historical Data
* Premium members only.
The historical data trend for Serina Therapeutics's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Serina Therapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Serina Therapeutics ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Serina Therapeutics's ROA % distribution charts can be found below:
* The bar in red indicates where Serina Therapeutics's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Serina Therapeutics (FRA:2BO) has a ROA % of -161.54% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Serina Therapeutics and its competitors. According to the industry distribution chart, Serina Therapeutics ranks #1308 out of 1419 companies in the Biotechnology industry, placing it in the top 92.2%.
Is Serina Therapeutics' ROA % too high?
Serina Therapeutics' current ROA % is -161.54%. Based on the distribution chart, Serina Therapeutics ranks #1308 out of 1419 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Serina Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Serina Therapeutics' ROA % compare to NRSN and IGC?
According to the Biotechnology industry distribution chart, Serina Therapeutics ranks #1308 out of 1419 companies for ROA %. This places Serina Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Serina Therapeutics and its competitors. Serina Therapeutics's current ROA % is -161.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Serina Therapeutics stock overvalued right now?
Serina Therapeutics (FRA:2BO) has a current ROA % of -161.54%. The current ROA % is -161.54%. Serina Therapeutics' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Serina Therapeutics (FRA:2BO), the current ROA % is -161.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
19GF Score
Get the complete analysis for FRA:2BO
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2BO has been successfully added to your 
